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ABSTRACT 46 
Mucosal Associated Invariant T (MAIT) cells are abundant in humans and 47 
recognise bacterial ligands. Here we demonstrate that MAIT cells are also 48 
activated during human viral infections in vivo. MAIT cells activation was 49 
observed during infection with Dengue virus, Hepatitis C virus, and 50 
Influenza Virus.  This activation – driving cytokine release and Granzyme B 51 
upregulation - is TCR-independent but dependent on IL-18 in synergy with 52 
IL-12, IL-15 and/or interferon-α/β. IL-18 levels and MAIT cell activation 53 
correlate with disease severity in acute Dengue infection. Furthermore, 54 
HCV treatment with interferon-α leads to specific MAIT cell activation in 55 
vivo in parallel with an enhanced therapeutic response. Moreover, TCR-56 
independent activation of MAIT cells leads to a reduction of HCV replication 57 
in vitro mediated by IFN-γ. Together these data demonstrate MAIT cells are 58 
activated following viral infections, and suggest a potential role in both 59 
host defence and immunopathology. 60 
 61 
 62 
  63 
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INTRODUCTION  64 
MAIT (mucosal associated invariant T) cells are an abundant and distinctive T 65 
cell subset first identified by Porcelli1 in 1993 in humans on the basis of the 66 
invariant V-alpha chain (Vα7.2-Jα33) and later described in mice2. MAIT cells 67 
comprise ~5-10 % of T-cells within the periphery and are found enriched in both 68 
the gut and in the liver - where in humans they may represent between ~12-50 % 69 
of T-cells3–6. In both mouse and man, MAIT cells are restricted to a bacterial 70 
riboflavin synthesis pathway-derived ligand presented by the conserved MHC-71 
Class I like molecule MR17,8. In vivo challenge models using riboflavin 72 
synthesising bacteria, such as Klebsiella species and mycobacteria, have 73 
confirmed an anti-bacterial role for MAIT cells9,10. MR1 tetramers loaded with the 74 
ligand rRL-6-CH2OH have allowed the specific detection of human and murine 75 
MAIT cells11. 76 
In recent years, a number of groups have elucidated the distinct phenotypic and 77 
functional profile of MAIT cells, characterised by the high expression of the C 78 
Type lectin CD161 (KLRB1 or NKR-P1A), and the capacity to secrete multiple 79 
cytokines, including IL-17, Interferon (IFN)-γ and TNF-α12–16.  The distinctive 80 
phenotype of MAIT cells appears to be driven by two key transcription factors, 81 
RORγt and PLZF3,6,17,18.  RORγt expression is linked to development of type 17 82 
function and expression of surface receptors such as IL23R and CCR619,20. This 83 
is consistent with mucosal defence and anti-bacterial functions and also 84 
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consistent with the bacterial specificity of the receptor. PLZF is critical for 85 
development of iNKT cells and may be responsible for a distinct set of “innate” 86 
phenotypic features, including marked upregulation of the pro-inflammatory 87 
cytokine receptors IL-18R and IL-12R21,22. This dual transcriptional drive 88 
suggests that MAIT cells may possess multiple parallel functionalities or modes 89 
of activation.   90 
Given the specificity of the TCR it appears that activation of MAIT cells in vivo is 91 
driven by responsiveness to bacteria (and some yeasts)23. However, given their 92 
“innate” phenotype, broad range of effector functions, and tissue distribution, we 93 
addressed the question of whether they may also have evolved to respond to 94 
viral infections in vivo. If so, this would markedly widen the role of MAIT cells in 95 
human infection.  96 
Here we addressed MAIT cell activation in response to a set of major human viral 97 
pathogens both in vivo and in vitro. In vivo, MAIT cells are activated in response 98 
to Dengue Virus (DENV), Hepatitis C Virus (HCV), and influenza virus. In vitro, 99 
DENV, HCV and influenza virus readily trigger MAIT cell populations in an IL-18 100 
dependent manner, in concert with other virally-driven pro-inflammatory 101 
cytokines, including IFN-α/β. Activation of MAIT cells in acute dengue correlated 102 
both with disease outcome and with IL-18 signals. Similarly, in vivo activation of 103 
MAIT cells during HCV therapy correlated with specific addition of IFN-α during 104 
therapy. Taken together, these data strongly implicate a role for MAIT cells in 105 
response to major virus infections of man and provide a mechanism for their 106 
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virus-responsive nature. Overall this significantly expands the pathogen response 107 
repertoire of this abundant human T cell subset. 108 
 109 
RESULTS  110 
MAIT cell activation during acute viral infections in vivo 111 
Whether human MAIT cells respond during acute viral infections remains unclear. 112 
To address this we analysed MAIT cell activation in DENV and influenza virus 113 
infection. In this study, MAIT cells were defined as CD161++Vα7.2+ 114 
CD8+CD4−CD3+ T cells. DENV infection presents with a rapid onset of a febrile 115 
illness, which lasts around a week. After the virus has been cleared and fever 116 
drops, patients follow two distinct courses: an uncomplicated resolution (Dengue 117 
Fever; DF) or a severe course associated with organ dysfunction and 118 
haemorrhage (Dengue Haemorrhagic Fever; DHF). The determinants driving 119 
outcome are still poorly understood. However, an aberrant immune response, 120 
around the day of defervescence, is thought to play an important role in the 121 
pathogenesis. We analysed MAIT cells in a longitudinal study of peripheral blood 122 
mononuclear cells (PBMC) from a cohort of patients with DHF or DF. Blood 123 
samples were collected at different time points during the acute phase of 124 
infection and dates were named in relation to the day fever subsided (day of 125 
defervescence, day 0). Samples taken ten or more days after the day of 126 
defervescence (day >10) were considered convalescent. We found a small but 127 
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significant reduction in MAIT cell frequencies between the acute phase (day 0) 128 
and the convalescent phase (day >10) of infection (Fig. 1a+b), but no differences 129 
in MAIT cell frequency between DHF and DF patients (Fig. 1c).  130 
Analysis of CD38 revealed marked in vivo activation of MAIT cells (Fig. 1d+e), 131 
which increased over the course of infection and peaked at a critical moment for 132 
DENV infected patients – the day of defervescence. Interestingly, patients who 133 
developed the severe form of dengue had higher levels of MAIT cell activation as 134 
judged by CD38 expression compared to DF patients over the course of acute 135 
infection (Fig. 1f). MAIT cell activation resolved to healthy control levels in the 136 
convalescent sample (Fig. 1d+e).  137 
Granzyme B expression was also assessed due to its tight regulation in MAIT 138 
cells, and its absence in cells from healthy donors3,24. Furthermore, upregulation 139 
of Granzyme B is associated with the acquisition of cytolytic function by MAIT 140 
cells24,25. We therefore analysed Granzyme B function in acute dengue and found 141 
this followed the same time course as that of CD38 (Fig. 1g-i).  142 
Given their role in mucosal defence, we next addressed the activation of MAIT 143 
cells in response to influenza virus, a virus with a segmented genome of 144 
negative-sense RNA. Again, patients with acute, severe influenza virus infection 145 
had reduced MAIT cell frequencies and an increase in Granzyme B expression 146 
on MAIT cells (Fig. 1j-m).  147 
 148 
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Taken together, our results indicate substantial triggering of MAIT cells in vivo 149 
during acute viral infection.  150 
 151 
MAIT cell activation during chronic viral infection in vivo 152 
MAIT cells are found at high frequencies within the liver in both healthy and 153 
diseased states3,5,13,26. Therefore, we analysed MAIT cell activation during 154 
chronic infection with HCV, like DENV, a member of the Flaviviridae family of 155 
positive-sense RNA viruses. We examined MAIT cell frequency and phenotype in 156 
the PBMC of patients with persistent and resolved HCV infection (spontaneously 157 
or after therapy). In all HCV patients, regardless of status, we observed a 158 
reduction in MAIT cell frequencies compared to healthy controls (Fig. 2a). 159 
However, we only observed upregulation of Granzyme B in patients with 160 
prolonged HCV infection (including those who had subsequently responded to 161 
antiviral therapy; Fig. 2b+c), and not in those patients with prior short-lived 162 
viremia at a distant time-point associated with acute resolving infection (thus 163 
more akin to convalescent DENV infection). Our results indicate substantial 164 
activation of MAIT cells in vivo both during acute and chronic viral infections. 165 
 166 
Viral MAIT cell activation in vitro   167 
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Having observed MAIT cell activation in vivo during acute and chronic viral 168 
infections, we next established in vitro models for viral infections using PBMCs or 169 
human CD8+ T cells, co-incubated with infected or virus-treated Dendritic Cells 170 
(DCs) or macrophages as Antigen Presenting Cells (APC).  171 
MAIT cells were readily and specifically activated in response to DENV treated 172 
APCs (MOI=1), as indicated by production of IFN-γ and Granzyme B (Fig. 3a+b), 173 
as well as, expression of CD38, with minimal production of TNF-α 174 
(Supplementary Fig. 1a-c). Activation was dependent on the presence of APCs 175 
as DENV alone did not activate MAIT cells (data not shown). 176 
We next examined activation of MAIT cells in vitro in response to influenza virus. 177 
APCs incubated with influenza virus (MOI=1) promoted strong MAIT cell 178 
activation, inducing upregulation of CD69 and IFN-γ (with minimal TNF-α 179 
secretion), in a dose-dependent manner (Fig. 3c+d). Also, Granzyme B 180 
expression was induced (Fig. 3e). This activation was not restricted to laboratory-181 
adapted influenza virus strains, but also was seen in response to recently-182 
circulating strains of influenza A and B (Fig. 3f). Interestingly, MAIT cell activation 183 
was also readily induced using PBMCs instead of purified APCs (Supplementary 184 
Fig.1d). Moreover, influenza virus exposure of purified monocyte, macrophage 185 
and DC populations all led to MAIT cell activation (Supplementary Fig. 1e).  186 
Finally, we tested the impact of HCV on MAIT cells in vitro. MAIT cells expressed 187 
IFN-γ and Granzyme B (Fig. 3g+h), as well as CD69 in response APC’s treated 188 
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with HCV (MOI=1), in a dose dependent and specific manner (Supplementary 189 
Fig. 1f-i). 190 
Taken together, we demonstrate that MAIT cells are activated in vitro in response 191 
to DENV, influenza virus and HCV-exposed APCs.  192 
 193 
Viral MAIT cell activation is dependent on cytokines 194 
Next, we investigated the mechanisms of MAIT cells activation in response to 195 
viruses. The ligand presented by MR1 is derived from the riboflavin synthesis 196 
pathway, which is not found in host cells or viruses7. Consistent with this, using 197 
the models described above, we confirmed by antibody blocking of MR1 that 198 
MAIT cell activation was TCR-independent for all the viruses tested (Fig. 4 a-c).   199 
As activation was TCR-independent, we explored triggering of MAIT cells by 200 
cytokines. Previously, we have shown that TLR8 is capable of inducing IFN-γ 201 
expression in MAIT cells via IL-12 and IL-1826. Additionally, IL-15 can specifically 202 
activate distinct functions of MAIT cells in synergy with IL-12 and/or IL-18, in a 203 
dose-dependent manner (Supplementary Fig. 2 and 3)27. We extended this 204 
finding by exploring responses to a range of TLR ligands in PBMCs and found 205 
endosomal TLR3 was also a potent activator (Supplementary Fig. 4). As with 206 
TLR8, TLR3 induced MAIT cells activation via IL-18 and IL-12 and not MR113,28. 207 
TLR sensing by APC’s can occur in the absence of viral replication29,30. To 208 
assess the requirement of viral replication for MAIT cell activation, we used UV-209 
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irradiation of the viruses, which prevents transcription or replication. UV-irradiated 210 
DENV was no longer able to activate MAIT cells (Supplementary Fig. 5a). In 211 
contrast, UV-irradiated HCV and influenza virus were still able to activate MAIT 212 
cells, although less efficiently compared to untreated virus (Supplementary Fig. 213 
5b+c). Accordingly, DENV productively infects APCs, whereas productive 214 
influenza virus and HCV infection is limited in both primary and stem cell derived 215 
human APCs (Supplementary Fig. 5d-f)31–33. Furthermore, the level of DENV 216 
infection correlated with MAIT cell IFN-γ expression (Supplementary Fig. 5e). 217 
We next assessed blockade of IL-12, IL-18 and IL-15 in the in vitro virus models. 218 
Fig. 4d reveals that IL-12 and IL-18 had the most significant impact on DENV-219 
dependent MAIT cell activation using DC’s, with anti-IL-18 blockade alone 220 
leading to complete suppression of IFN-γ expression. IL-18 was the most 221 
abundant cytokine induced in DC’s in response to DENV (Fig. 4e).  222 
Anti-IL-18 also inhibited activation of MAIT cells induced by influenza virus, a 223 
result observed using purified APCs (Fig. 4f) or PBMC’s (Supplementary Fig. 6a). 224 
Blockade of IL-12 and IL-15 alone or in combination had a limited impact in 225 
influenza virus-induced MAIT cell activation using macrophages (Fig. 4f). 226 
Accordingly, IL-18, but not IL-12 or IL-15 was secreted by macrophages after 227 
incubation with influenza virus (Fig. 4g).  228 
Similar to DENV and influenza virus, IL-18 played a dominant role in HCV-229 
induced MAIT cell activation  (Fig. 4h). Addition of further blockade with anti-IL-15 230 
was required to achieve maximal suppression. We assessed expression of IL-12, 231 
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IL-15 and IL-18 on macrophages after incubation with HCV (Fig. 4i). No IL-15 232 
protein was detected, yet IL-15R (responsible for IL-15 trans-presentation34) was 233 
upregulated by macrophages in response to HCV, as measured by qPCR 234 
(Supplementary Fig. 6b).   235 
Overall, these experiments indicate a mechanism by which viruses can activate 236 
MAIT cells, dependent on viral sensing and cytokines, with a key role for IL-18, 237 
and independent of MR1 and TCR. 238 
 239 
Virally-triggered IL-18 correlates with MAIT cell 240 
activation 241 
Having identified IL-18 as an important cytokine for viral MAIT cell activation in 242 
vitro, we further explored its relevance in vivo. In DENV infection, IL-18 levels in 243 
plasma were markedly increased during the acute phase compared to the 244 
convalescent phase of infection and healthy controls (Fig. 5a). In addition, 245 
patients suffering from the severe form of dengue (DHF) had significantly higher 246 
levels of IL-18 over the course of acute infection compared to patient with DF 247 
(Fig. 5b). Interestingly, expression of the IL-18 receptor (IL-18R) on MAIT cells 248 
was upregulated during the acute phase of infection and resolved to healthy 249 
control levels in the convalescent samples (Fig. 5c). As observed for IL-18, 250 
patients with DHF revealed higher expression of IL-18R on MAIT cells compared 251 
to patient with DF (Fig. 5d+e). Thus, levels of IL-18 in plasma and expression of 252 
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IL-18R on MAIT cells in vivo are upregulated during the acute phase of infection, 253 
especially in those patients suffering from DHF. These findings show an 254 
association with increased activation of MAIT cells and disease severity in 255 
dengue patients (Fig. 1f and Fig. 5f). These results are not restricted to DENV 256 
infection since IL-18 protein (Fig. 5g) and mRNA (Fig. 5h) were found readily in 257 
liver tissues from patients with HCV infection. 258 
Overall these data indicate that IL-18 is not only a dominant factor during in vitro 259 
viral MAIT cell activation, but also plays an important role in vivo. 260 
 261 
MAIT cells respond to Type I Interferons in vitro and in 262 
vivo 263 
Type I IFNs are also important cytokines known for their strong antiviral activity. 264 
Previous reports have determined a crucial role of IFN-α/β during DENV35, 265 
influenza36 and HCV37 infections in limiting viral replication and disease severity. 266 
We therefore addressed whether IFN-α/β can also influence MAIT cell activation 267 
in vitro and in vivo.  268 
First we tested whether IFN-α/β could trigger MAIT cells alone or in combination. 269 
We found IFN-γ secretion by MAIT cells in response to IFN-α/β in combination 270 
with IL-12 and IL-18, but not IL-15 (Fig. 6a), in a dose-dependent manner 271 
(Supplementary Fig. 7). Next, we confirmed that these TCR-independent 272 
responses to cytokines are shared with other CD161++ T cell subsets, but not 273 
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CD161- T cell populations. CD161++CD8+ T cells that lack expression of the 274 
Vα7.2Jα33 TCR (Supplementary Fig. 8a), CD161++ Vα7.2Jα33+ CD4 T cells 275 
(Supplementary Fig. 8b) and CD4-CD8- T cells (Supplementary Fig. 8c) could all 276 
be triggered in response to cytokines, unlike CD161- T cell populations 277 
(Supplementary Fig. 8d). This is in agreement with our previous findings which 278 
suggest that CD161 expressing lymphocytes display a shared innate response to 279 
cytokines16.  280 
To further explore the role of type I IFNs during viral MAIT cell triggering, we 281 
used a vaccinia virus-encoded, soluble type I IFN receptor (B18R)38. 282 
Macrophages treated with HCV in vitro were incubated in the presence of B18R 283 
and T-cells overnight. Blockade of type I IFNs by B18R inhibited MAIT cell IFN-γ 284 
secretion (Fig. 6b), CD69 expression (Fig. 6c) and Granzyme B upregulation 285 
(Fig. 6d).  286 
IFN-α has been an important component of HCV treatment. This gave us an 287 
opportunity to explore whether type I IFNs could contribute to MAIT cell activation 288 
in vivo.  We measured the activation marker CD69 on MAIT cells from HCV 289 
patients taking part in a clinical trial in which they were treated with either 290 
Sofosbuvir (SOF) + Ribavirin (RBV) + pegylated IFN (PEG-IFN), or only SOF + 291 
RBV, without PEG-IFN. Interestingly, CD69 expression on MAIT cells was 292 
upregulated only in the treatment group receiving PEG-IFN (Fig. 6e), which 293 
corresponded with a significantly higher sustained virologic response rate39. High 294 
CD69 upregulation was specific to CD161++MAIT cells and not observed on 295 
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CD161-CD8+ or CD4+ T cells  (Supplementary Fig. 9). These data demonstrate 296 
that type I IFNs can contribute to MAIT cell activation in vitro and in vivo. 297 
 298 
Activated MAIT cells can limit HCV replication 299 
Finally, we explored whether viral MAIT cell activation can have a functional 300 
impact on virus replication. We stimulated sorted MAIT cells in a TCR-301 
independent manner (IL-12 and IL-18) and confirmed activation by measurement 302 
of IFN-γ secretion (Fig. 7a). The cell supernatants of unstimulated and stimulated 303 
MAIT cells were transferred to a hepatocyte lines infected with HCV expressing 304 
luciferase, allowing measurement of HCV replication. The activated MAIT cell 305 
supernatants were able to potently suppress HCV replication while no activity 306 
from control supernatants (Fig. 7b) or from IL-12 and IL-18 (data not shown) 307 
addition to hepatocytes was seen. Diluting the activated MAIT cell supernatant 308 
reduced the suppression of HCV replication in a dose-dependent manner (Fig. 309 
7c). Addition of anti-IFN-γ reversed the HCV suppression by activated MAIT cell 310 
supernatants (Fig. 7d). In an extension of the experimental set up using virally-311 
induced activation to trigger MAIT cells, supernatants from MAIT cells incubated 312 
with HCV-treated macrophages reduced HCV replication in the hepatocyte 313 
reporter cell lines compared to mock-treated macrophages (Supplementary Fig. 314 
10). These results indicate that activation of MAIT cells by viral triggers induces 315 
responses that can impact on viral replication in vitro.  316 
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 317 
DISCUSSION 318 
MAIT cells are an abundant human T-cell population with a semi-invariant TCR 319 
determining bacterial specificity. It has previously been considered that MAIT 320 
cells were not responsive to viral infection40. However, in this study we provide 321 
data to show MAIT cells are also readily and specifically activated by pathogenic 322 
viruses in vivo and in vitro. Furthermore, we define mechanisms that allow this 323 
virally-driven activation, and show they are distinct in the different viral settings. 324 
 325 
The in vivo data shows that there is evidence of MAIT cell activation in response 326 
to DENV, HCV and influenza virus. Of these the most striking is the data from 327 
acute DENV infection as it is clear that such activation is profound and rapid in 328 
this severe clinical setting. Of note those patients who went on to develop DHF 329 
exhibited significantly higher levels of activation as judged by CD38 expression. 330 
This suggests the MAIT cell response could contribute to the pathophysiology of 331 
this condition. The correlation between levels of IL-18, levels of IL18R and MAIT 332 
cell activation suggests an important role for IL-18 in this activation process, 333 
consistent with the in vitro mechanisms demonstrated. In DENV, HCV and 334 
influenza virus infection we found clear evidence of activation of the MAIT cells, 335 
as judged by upregulation of Granzyme B (which is tightly regulated in MAIT 336 
cells24). In addition, we noted a decrease in circulating MAIT cell frequencies. 337 
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The mechanism for this is not clear. It may result from translocation of some cells 338 
from blood to tissues, or it could result from activation-induced cell death as has 339 
been suggested for HIV infection41.  340 
 341 
The data presented are correlative – however probing a non-redundant role in 342 
animal models is not straightforward. In mice the MAIT cell population is a very 343 
small minority compared to the frequencies of iNKT cells, which have overlapping 344 
functions and innate cytokine responsiveness42. In humans, the situation is 345 
reversed, with MAIT cell frequencies exceeding those of iNKT cells by 1-2 logs17. 346 
Existing data indicate a functional antiviral role for iNKT cells in control of virus 347 
infections in tissues such as lung, in mouse models: given similar molecular 348 
mechanisms of activation apply, and similar effector functions are induced, it 349 
seems reasonable to extrapolate from this that MAIT cell activity would play a 350 
parallel role in human infection 43. Emerging models with increased MAIT cell 351 
frequencies in mice may help address this question using new in vivo models44.  352 
 353 
MR1 tetramers unequivocally identify MAIT cells, but these reagents are not yet 354 
widely available. In this study we used CD161++Vα7.2+ as a surrogate marker 355 
for MAIT cells, which is a commonly used staining approach and includes the 356 
majority of tetramer-positive MAIT cells6,45. We further defined MAIT cells as 357 
CD8+CD4−CD3+ T cells and for in vitro experiments, PBMC’s from healthy 358 
individuals were used. CD8 is expressed by the majority of MAIT cells, and CD4 359 
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only by a small proportion of MAIT cells45. This approach has been used in recent 360 
transcriptional studies and allows ready comparison with related CD161-361 
expressing subsets16. Future studies using MR1 tetramers are needed to further 362 
establish the distribution of MAIT cell phenotype in virally infected humans in 363 
more detail. As we did not have access to the tetramer, the observed loss of 364 
MAIT cells in virally infected patients may be potentially explained by down-365 
regulation of CD161, as previously suggested46,47. However, Fernandez et al. 366 
showed that in HIV-1 infected patients, MR1 tetramers do not bind CD161- 367 
Vα7.2+ T cells48, and the loss of MAIT cells in the periphery may be due to 368 
recruitment to the site of infection or activation-induced cell death. Of note, our 369 
data are not restricted to CD161++Vα7.2+ cells but also includes responses from 370 
the minority CD161++Vα7.2- cells, which we have previously described as 371 
sharing phenotypic and functional properties with MAIT cells and which likely also 372 
include some recently described Vα7.2- MR1-restricted T cell populations49,50.  373 
 374 
The mechanisms we have explored reveal a central role for IL-18 in virus-375 
induced activation12,16. However, the critical co-stimulation was not restricted to a 376 
single cytokine. In the case of HCV we repeatedly observed an important role for 377 
IL-15. IL-15 levels in these experimental conditions were very low, but 378 
upregulation of IL-15R was seen and importantly antibody-blockade of IL-15 379 
revealed a clear role for this cytokine. Additionally, we observed a role for Type I 380 
IFNs in the activation of MAIT cells in response to HCV. This was clear in both 381 
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addition and blockade experiments and is consistent with data from NK cells, 382 
where such cytokine mediated activation is described51.  383 
The cytokine activation of MAIT cells was mediated by APCs with a role for viral 384 
sensing and replication. In the case of DENV, viral replication was required for 385 
MAIT cell activation and this was positively correlated with the level of productive 386 
infection in the APC. Although we observed a reduction of MAIT cell activation in 387 
response to UV-irradiated HCV and IAV, replication does not play a key role in 388 
this context, since HCV and Influenza poorly replicate in macrophages31,32. As 389 
APC have continual and extensive endocytic activity, viral recognition can occur 390 
through endocytosis of viral particles as well as through direct infection29,52. Using 391 
TLR agonists, we found that both surface and endocytic TLRs can trigger MAIT 392 
cells, in particular viral pathogen-associated molecular patterns (PAMPs).  393 
Using murine bone marrow derived DCs, Le Bourhis et al. has previously shown 394 
that MAIT cells are not responsive to viral infection40. This discrepancy is likely 395 
due to the use of murine, rather than human cells, which may reflect differential 396 
abilities in secreting, as well as, responding to cytokines.    397 
 398 
IFN-α mediated activation of MAIT cells is clinically and functionally relevant, as 399 
demonstrated in vivo in the well-controlled BOSON clinical trial. In addition to 400 
directly acting antiviral drugs (sofosbuvir in combination with ribavirin) IFN-α was 401 
included in one arm only and associated with MAIT cell activation and an 402 
enhanced therapy response39. It is possible that MAIT cells act as local amplifiers 403 
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of IFN-α mediated therapies, contributing to an antiviral effect through secretion 404 
of further local antiviral cytokines or potentially via clearance of infected cells. 405 
The specific activation by type I IFNs appears to be important evidence in favour 406 
of an evolution of MAIT cells in response to viral signals. Although Type I IFN 407 
signalling is not exclusive to virus infections, a wealth of data links IFN pathways 408 
with antiviral defence and we propose that MAIT cells form an important part of 409 
this network in humans. Of note, IFN-α signalling alone was insufficient to fully 410 
activate MAIT cells, indicating a potentially fail-safe mechanism to prevent 411 
harmful over-activation.  412 
 413 
The secondary consequences of MAIT cell activation could be of significance for 414 
both protection and immunopathology. Activation of MAIT cells in tissues could 415 
provide both direct and indirect antiviral effects. HCV, for example, is known to be 416 
highly sensitive to T-cell derived IFN-γ53,54.  Accordingly, we found that activation 417 
of MAIT cells by HCV induced responses that limited HCV replication in vitro, in 418 
an IFN-γ dependent manner. Thus the local activation of MAIT cells can be 419 
plausibly correlated with a direct antiviral function in vivo.    420 
Loss of MAIT cell frequencies (as we have observed in blood) may contribute to 421 
impairment of both viral and bacterial control, whereas excess cytokine secretion 422 
by MAIT cells may lead to immunopathologic outcomes. For example, high levels 423 
of MAIT cell activation could contribute to the cytokine “storm” associated with 424 
DHF and severe cases of influenza virus55,56. Activation-induced loss of MAIT 425 
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cells is potentially relevant in the context of influenza virus infection, which is 426 
epidemiologically associated with secondary bacterial pneumonia due to 427 
Staphylococcus aureus or Streptococcus pneumonia57,58.  Both of these 428 
organisms possess the MAIT cell ligand7,40 and it is plausible that depletion of 429 
MAIT cells in situ could lead to transient impairment of local control of these 430 
pathogens. Interestingly, the transcription factor PLZF, which likely drives the 431 
innate phenotype and functionality of MAIT cells, may also contribute to the 432 
induction of activation-induced cell death, through upregulation of specific 433 
intracellular caspases59.  434 
 435 
In conclusion, human MAIT cells are activated in response to virus infections (as 436 
illustrated by a simplified model depicted in Supplementary Fig. 11), through 437 
overlapping mechanisms dependent on the virus and likely the environment and 438 
cell types affected. These data extend the likely functions of these abundant 439 
human lymphocytes well beyond their traditional confines. Modulation of this cell 440 
subset (and related CD161+ T cell subsets16,60–62) could provide a novel 441 
opportunity to promote antiviral defence or limit immunopathology. 442 
 443 
MATERIALS AND METHODS 444 
Patient samples 445 
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All samples were collected with appropriate patient consent and local research 446 
ethics committee approval. Samples were frozen and stored at −80°C until 447 
examined. Healthy donors were supplied by the NHS blood service without any 448 
further donor information.  The study on DENV patient samples was approved by 449 
the Scientific and Ethical Committee of the Khon Kaen Hospital in Thailand and 450 
the Riverside Ethics Committee in the UK (06/Q0401/22). Laboratory 451 
confirmation of DENV infection was determined by RT-PCR detection of DENV 452 
nucleic acid (which also confirmed the infecting serotype) or seroconversion in an 453 
ELISA of IgM. Secondary infection was defined based on the ratio of DENV-454 
specific IgM to IgG <1.2 on or after day 6 of illness. Disease severity was 455 
classified according to 1997 World Health Organization criteria. Of the patients 456 
enrolled in the study, ten patients were classified as mildly symptomatic of 457 
dengue fever, and ten patients were classified as severely symptomatic of 458 
dengue haemorrhagic fever, with plasma leakage and bleeding (Supplementary 459 
Table 1). The day of defervescence was defined as day 0, the day before 460 
defervescence as day −1, the day after defervescence as day +1, and so forth. 461 
Peripheral blood mononuclear cells were isolated from whole blood by Ficoll-462 
Hypaque density-gradient centrifugation at various time points during 463 
hospitalization and cryopreserved until further use. 464 
Patients with influenza virus infection requiring hospitalisation were recruited from 465 
two hospitals based in Oxford and Glasgow during the 2009 H1N1 pandemic 466 
under ethical approval (09/H0606/92). Influenza virus infection was diagnosed 467 
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using an in-house generic influenza A real time PCR assay based on the Matrix 468 
gene and confirmed with swine-origin H1N1/09 specific Matrix gene PCR 63,64.  469 
Patients had concomitant conditions as documented in Supplementary Table 2, 470 
but were not on immunosuppressants or steroids at the point of sampling. Two 471 
patients were pregnant, and one was six days post-partum. PBMC samples 472 
from HCV patients (Supplementary Table 3) were collected from the Hepatitis 473 
Clinic at the John Radcliffe Hospital, Oxford, UK and consented according to a 474 
locally approved protocol (COREC 04.OXA.010). Liver biopsy specimens were 475 
obtained from patients with HCV infection (n=55) at S. Bortolo Hospital, Vicenza, 476 
Italy and scored using the Ishak system. Control samples were normal adjacent 477 
tissue from 6 uninfected volunteers undergoing liver resection for other reasons 478 
(source Proteogenex, CA, USA). Trials were conducted in accordance with the 479 
Declaration of Helsinki, ethical approval was obtained from local ethics 480 
committees, and all patients provided written informed consent. Explanted HCV 481 
diseased liver tissues were obtained from QE transplant program and non-482 
diseased normal liver tissue was obtained from donor liver tissue surplus to 483 
clinical requirements. Normal liver was liver tissue from hepatic resection of 484 
colorectal metastasis. For studying MAIT cell activation in the context of HCV 485 
infection and Type I IFNs in vivo, PBMC from the BOSON clinical trial were used, 486 
as part of a collaboration between STOP-HCV and Gilead Sciences39,65. BOSON 487 
is a randomized, open-label, phase 3 study testing Sofosbuvir plus Ribavirin with 488 
or without pegylated IFN-alpha in patients with HCV Genotype 3 and Treatment-489 
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experienced cirrhotic patients with HCV Genotype 2 (Supplementary Table 490 
4).  This study was registered with the European Clinical Trials Database, 491 
number 2013-002641-11.  492 
 493 
Tissue staining 494 
Paraffin embedded human liver tissues sections were dewaxed using Clearene 495 
and IMS. Endogenous peroxidase was blocked by using 5% hydrogen peroxide 496 
followed by antigen retrieval using 10% EDTA buffer. Slides were blocked using 497 
casein buffer. Primary Rabbit IL-18 antibody LS-B2809, 1:50 dilution was applied 498 
for an hour followed by Vector Impress anti-rabbit secondary for 30 minutes in a 499 
staining chamber with rocking. Slides were then washed with PBS + Tween and 500 
Impress DAB substrate was applied for 2½ mins. Slides were then 501 
counterstained in Mayers haematoxylin and mounted in DPX. 502 
 503 
Cell culture 504 
Human PBMCs were isolated from leukocyte cones from healthy donors supplied 505 
by the NHS blood service. CD8+ T-cells were isolated from PBMCs using positive 506 
selection with MACS CD8+ microbeads (Miltenyi). Monocytes were enriched from 507 
PBMCs using MACS CD14+ microbeads (Miltenyi). Monocytes were 508 
differentiated into macrophages (macrophages or GM-MΦ), by incubating the 509 
CD14+ cells for 7 days in X-VIVOTM15 (Lonza), Pen/strep (Sigma-Aldrich), L-510 
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glutamine (Sigma-Aldrich) with 50 ng ml-1 GM-CSF (Miltenyi). Immature dendritic 511 
cells (imDC’s or DC’s) were obtained by culturing CD14+ cells for 4 to 5 days in 512 
the presence of 20 to 100 ng ml-1 GM-CSF (Miltenyi/First Link) and 25 ng ml-1 IL-513 
4 (Miltenyi/eBioscience). Where stated, MAIT cells were sorted using a Beckman 514 
Coulter MoFlo XDP. 515 
 516 
Viruses 517 
DENV serotype 2, strain 16681, was grown in C6/36 cells in Leibovitz’s L-15 518 
medium with L-glutamine and supplemented with 2% FCS. Culture medium was 519 
centrifuged and stored at −80 °C. The titres of virus were determined by a focus 520 
forming assay on Vero cells and expressed as focus-forming units (FFU) per ml. 521 
Briefly, virus was serially diluted and incubated with Vero cells for 2 h at 37°C. 522 
The monolayers were then overlaid with 1.5% carboxymethylcellulose and 523 
incubated at 37°C for 3 days. Virus foci were stained with anti-DENV E antibody 524 
(4G2) followed by peroxidase-conjugated anti-mouse Ig and visualized by the 525 
addition of DAB substrate. Infection rates of DENV infected DCs were assessed 526 
using intracellular staining against the non-structural DENV protein, NS3, by flow 527 
cytometry. The mouse monoclonal anti-DENV NS3 (E1D8) and anti-DENV E 528 
(4G2) were gifts from E. Harris and AFRIMS. 529 
10 ng RNA transcribed from genotype 2a HCV strain J6CF-JFH1,  (obtained from 530 
Prof. Bartenschlager66) was electroporated into Huh7.5 cells (obtained from 531 
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Apath) and were cultured for up to 3 weeks. Cell culture Supernatants were 532 
collected for up to 20 days post electroporation centrifuged and concentrated 533 
using an Amicon Ultra-15 (Millipore). This inoculum was used to infect huh7.5 534 
cells. The HCV titre was determined by immunofluorescence. Huh7.5 cells were 535 
fixed with methanolacetone, blocked with BSA/phosphate-buffered saline (PBS) 536 
solution, washed with PBS, stained with anti-HCV core primary antibody 537 
(Cambridge Biosciences), washed with PBS, and Alexa Fluor® 488 donkey 538 
polyclonal secondary antibody to Mouse IgG (ab150105, Abcam). To measure 539 
HCV replication a HCV luciferase reporter Jc1FLAGp7-nsGluc2A32 virus was 540 
used. Jc1FLAG(p7-nsGluc2A) was grown in naïve Huh-7.5 cells67 and the 541 
infectivity titer was determined by limiting dilution titration on naïve Huh-7.5 cells 542 
as median tissue culture infective dose (TCID50). To measure HCV replication, 543 
Huh-7.5 cells were plated in a 96-well plate and infected at an MOI of 0.1 for 6 h. 544 
After washing the Huh-7.5 cells, supernatants from (un)stimulated MAIT cells 545 
were added in the presence or absence of a neutralising IFN-γ (clone MD-1, 14-546 
7317-85 eBioscience) . Supernatants were harvested 4 days post infection and 547 
luciferase expression determined using the Renilla Luciferase Assay System 548 
(Promega) and a Berthold TriStar2 multimode reader LB 942. 549 
Influenza A/WSN/33 (H1N1) virus (WSN) was grown in Madin Darby Bovine 550 
Kidney (MDBK, obtained from the European Collection of Cell Cultures) cells in 551 
Minimum Essential Medium Eagle (MEM; Sigma) with 2 mM L-glutamine and 552 
0.5% fetal calf serum (FCS). To produce virus stocks, six 175 cm2 tissue culture 553 
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flasks containing sub-confluent MDBK cells were infected at low-multiplicity. After 554 
48 h of culture in a 37 °C humidified incubator, supernatants were harvested and 555 
clarified by low-speed centrifugation (30 min, 2000 g and 30 min, 18 000, 4°C). 556 
Next, WSN was concentrated through a 30% sucrose cushion by 557 
ultracentrifugation (90 min, 112 000 g, 4°C). Finally, WSN was purified on a 30–558 
60% sucrose gradient by ultracentrifugation (150 min, 209 000 g, 4°C).  The 559 
visible band of virus was drawn off with a needle. (Hutchinson, E. and Fodor, E., 560 
Nature Protocol Exchange, Purification of influenza virions by haemadsorption 561 
and ultracentrifugation,   562 
“http://www.nature.com/protocolexchange/protocols/3315”)68,69. Plaque assays 563 
were performed on MDBK cells using standard techniques. Influenza A (H3N2) 564 
virus A/England/691/2010 is a clinical strain isolated by Public Health England 565 
(PHE), as part of the MOSAIC project. Influenza B virus, B/Florida/04/2006 was 566 
derived from reverse genetics systems by de novo synthesis (GeneArt®).  567 
 568 
In vitro virus experiments 569 
Unless specified differently, for co-culture experiments using viruses, antigen 570 
presenting cells were treated with virus at a multiplicity of infection (MOI) of 1, as 571 
determined based on the viral titre and number of cells plated, for 90 to 120 572 
minutes at 37°C. Virus was washed off and isolated CD8+ T-cells were added for 573 
an additional 10-24 h, unless specified differently. In the case of the DENV 574 
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experiments, PBMC’s were added instead of isolated CD8+ T-cells.  In the case 575 
of influenza virus, WSN virus was used, unless specified differently. 576 
 577 
In vitro cytokine stimulations 578 
For cytokine stimulation experiments, isolated CD8+ T-cells or PBMC’s were 579 
stimulated for 24 h with 50 ng ml-1 IL-12 (Miltenyi Biotech), 50 ng ml-1 IL-18 (R&D 580 
Systems Europe), 50 ng ml-1 IL-15 (Miltenyi Biotech), or 2000 U ml-1 IFN-α 581 
(Sigma-Aldrich), or 50 ng ml-1 IFN-β (Miltenyi Biotech) or combinations thereof. 582 
For blocking experiments, neutralising agents were added into the culture 583 
together with the CD8+ T-cells or PBMC’s. Blocking antibodies against IL-584 
12p40/70 (508804, eBioscience), IL-12p70 (MAB219-100, R&D), IL-15 585 
(MAB2471, R&D), or IL-18 (D044-3, MBL International, USA), IFN-γ (14-7317-85,  586 
eBioscience) or MR1 (361102, Biolegend) were used at 5-10 µg ml-1. Type I IFN 587 
was blocked using 1 µg ml-1 B18R (34-8185-81, eBioscience).  588 
   589 
Flow Cytometry 590 
Antibodies/dyes and dilutions used were: viability dye Live/Dead fixable-violet 591 
(L34955, Invitrogen, 1:1250), CD3-eFluor450 (48-0038, eBioscience, 1:100), 592 
CD3-PECy7 (25-0038, eBioscience, 1:100), CD4-VioGreen (130-096-900, 593 
Miltenyi Biotech, 1:50), CD8-VioGreen (130-098-062, Miltenyi Biotech, 1:50), 594 
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CD8-V450 (560347, BD, 1:50), CD8-PerCP.Cy5.5/PerCP (301032, Biolegend, 595 
1:100), CD38-APC (555462, BD, 1:50), CD69-FITC (11-0699, eBioscience, 596 
1:40), CD161-APC (130-098-908, Miltenyi Biotech, 1:100), CD161-PE (130-099-597 
193, Miltenyi Biotech, 1:100), IFN-γ-FITC (130-091-641, Miltenyi Biotech, 1:50), 598 
IFN-γ-APCCy7 (502529 Biolegend, 1:50), Vα7.2-PE/PeCy7/APC/FITC 599 
(351705/351711/351707/351703, Biolegend, 1:50). Granzyme B-APC (MHGB05, 600 
Invitrogen), IL-18Ra-APC (17-7183-41, eBioscience, 1:50), TNF-α-PeCy7 601 
(502929, Biolegend, 1:100). All data was acquired on a MACSQuant (Miltenyi 602 
Biotech) or a BD FACSVerse (BD) and analyzed on FlowJo (Tree Star Inc.). 603 
Gating strategy is shown in Supplementary Fig. 12. 604 
 605 
Cytokine measurements 606 
Cytokines levels in this study were measured from cell culture supernatants or 607 
heparin plasma samples. Cell culture supernatants from macrophages treated 608 
with mock, HCV or influenza A were collected at 48 h. Cell culture supernatants 609 
from DCs treated with mock or DENV were collected at 42 h. Heparin plasma 610 
samples were collected from DENV infected patients at different phases of illness 611 
or from healthy controls. Cell culture supernatants and heparin plasma samples 612 
were frozen at -80˚C until further use. Cytokine levels were analysed using Bio-613 
Plex human cytokine kits (BioRad) and acquired on a Luminex 100 (Luminex) or 614 
a Bioplex 200 reader (BioRad) according to the manufacturer’s instructions.   615 
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 616 
Statistical analysis 617 
Statistical analysis was carried out with GraphPad Prism software. Statistical 618 
significance was reported as ns P > 0.05; * P ≤ 0.05; **P ≤ 0.01; *** P ≤ 0.001; 619 
**** P ≤ 0.0001. Error bars on graphs represent SEM. Mann Whitney test was 620 
used to calculate significance levels between two groups. Wilcoxon matched-621 
paired test was used to calculate significance levels between two paired groups. 622 
For comparisons of means from multiple groups against one control group the 623 
Kruskal–Wallis with Dunn’s multiple comparison post-test analysis was 624 
performed. Spearman rank correlation analysis was used to calculate 625 
correlations. Sample sizes were adequate to detect large effects between groups, as 626 
determined by the reproducibility and variability of each particular experiment and limited 627 
by the availability of patient samples. No randomization or blinding was used. 628 
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 893 
Figure Legends 894 
Figure 1 MAIT cell activation during acute viral infections in vivo. PBMC’s from 895 
healthy controls (HC, n=5-10), patients suffering from severe dengue (DHF, n=2-896 
10), dengue (DF, n=4-10), or acute, hospitalised patients infected with influenza 897 
A virus (n=7-9) were analysed by flow cytometry by gating on live 898 
CD3+CD8+CD161++Vα7.2+ (MAIT) cells. (a, d, g) representative flow cytometry 899 
plots. (b, e, h) Comparison between acute (day 0) and convalescent phase (day 900 
>10) of infection. (c, f, i) Comparison between DHF and DF patients.  (j-m) 901 
Acute, hospitalised patients infected with influenza virus. (b, c, j, k) MAIT cell 902 
frequency as a proportion of the CD8+ T cell population. (e, f) Percentage of 903 
CD38 expression by MAIT cells. (h, i, l, m) Percentage of Granzyme B 904 
expression by MAIT cells. Statistical significance was determined with a Wilcoxon 905 
matched-paired test (b, e, h) or Mann-Whitney test (j, k). Bars represent means ± 906 
s.e.m.  ns > 0.05,  *P  0.05, **P ≤  0.01, ***P ≤  0.001, ****P ≤  0.0001. 907 
Abbreviations: conv, convalescent; DENV, Dengue Virus; DF, dengue fever; 908 
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DHF, dengue haemorrhagic fever; Gr B, Granzyme B; HC, healthy control; ICU, 909 
Intensive Care Unit; IAV, Influenza A Virus  910 
 911 
Figure 2 MAIT cell activation during chronic viral infection in vivo. PBMC’s from 912 
healthy controls (n=20-23) or patients (n=12-25) with persistent (treatment naïve, 913 
REL, NR) and resolved HCV infection (SVR, SC) were analysed by flow 914 
cytometry by gating on live CD3+CD8+CD161++Vα7.2+ (MAIT) cells. (a) MAIT cell 915 
frequency as a proportion of the CD8+ T cells. (b, c) Granzyme B expression by 916 
MAIT cells. (b) Representative flow cytometry plots. Bars represent means ± 917 
s.e.m. Statistical significance was determined with Kruskal-Wallis test followed by 918 
Dunns’ test. ns > 0.05,  *P  0.05, **P ≤  0.01, ***P ≤  0.001, ****P ≤  0.0001. 919 
Abbreviations: HC, Healthy Control; HCV, Hepatitis C Virus; Gr B, Granzyme B; 920 
REL / NR, relapse / non-response; SC, spontaneous clearance; SVR, Sustained 921 
virological response; tr., treatment. 922 
 923 
Figure 3 Viral MAIT cell activation in vitro. MAIT cells from healthy individuals 924 
were analysed by flow cytometry, gated on live CD3+CD161++Vα7.2+ cells. (a, b) 925 
PBMC’s (n=7) were co-cultured with autologous monocyte derived DC’s exposed 926 
to DENV (MOI=1) as described in “methods”. (c-e) CD8+ T cells isolated from 927 
PBMC’s (n=11-12) were co-cultured with IAV-exposed macrophages (MOI=1) as 928 
described in “methods”, unless indicated otherwise. (f) CD8+ T cells isolated from 929 
PBMC’s (n=11-12) were co-cultured with macrophages exposed to the clinical 930 
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H3N2 Influenza A strain (A/England/691/2010 (n=7)) or Influenza B 931 
(B/Florida/04/2006 (n=8)) (MOI=1) as described in “methods”. (g, h) CD8+ T cells 932 
isolated from PBMC’s (n=7-12) co-cultured with macrophages exposed to HCV 933 
(MOI=1) as described in “methods”. Proportion of MAIT cells producing IFN-γ (a, 934 
c, d, f, g), TNF-α (c, d), CD69 (c, d) or Granzyme B (b, e, h). (d) Representative 935 
flow cytometry plots. All data are representative from at least two independent 936 
experiments. Bars represent means ± s.e.m. Statistical significance was 937 
determined with Kruskal-Wallis test followed by Dunns’ test (f) or Mann-Whitney 938 
test (a, b, e, g, h). ns > 0.05,  *P  0.05, ***P ≤  0.001, ****P ≤  0.0001. 939 
Abbreviations: DC, Dendritic Cells, DENV, Dengue Virus; Eng, England; Flor, 940 
Florida; HC, Healthy Control; HCV, Hepatitis C Virus; Gr B, Granzyme B; IAV, 941 
Influenza A Virus; MΦ, macrophage; MOI, multiplicity of infection; REL / NR, 942 
relapse / non-response; SC, spontaneous clearance; SVR, Sustained virological 943 
response; tr., treatment. 944 
 945 
Figure 4 Viral MAIT cell activation is dependent on cytokines. (a-d, f, h) Isotype 946 
control, anti-MR1, anti-IL-12, anti-IL-15 and/or anti-IL-18 antibodies were added 947 
to a co-culture exposed to DENV (a, d, n=3-6), IAV (b, f, n=5-29), or HCV (c, h, 948 
n=7-16). IFN-γ expression by MAIT cells (gated on live 949 
CD3+CD8+CD161++Vα7.2+ cells) was analysed by flow cytometry and is shown 950 
relative to the isotype control. (e, g, i) IL-12p70, IL-15 and IL-18 levels secreted 951 
by virus-exposed APC’s. (e) DENV-exposed DC’s (n=4) at 42 h. (g) IAV-exposed 952 
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macrophages (n=7) at 48 h. (i) HCV-exposed macrophages (n=7) at 48 h. Data 953 
are representative from at least two independent experiments. Bars represent 954 
means ± s.e.m. Statistical significance was determined with the Mann-Whitney 955 
test (a-c, e, g, i) or Kruskal-Wallis test followed by Dunns’ test or Mann-Whitney 956 
test (d, f, h). ns > 0.05,  *P  0.05, ***P ≤  0.001, ****P ≤  0.0001. Abbreviations: 957 
DENV, Dengue Virus; HCV, Hepatitis C Virus; IAV, Influenza A Virus; ND, Not 958 
Detected. 959 
 960 
Figure 5 Virally-triggered IL-18 correlates with MAIT cell activation (a-d) PBMC’s 961 
from healthy controls (n=10) or patients suffering from severe dengue (DHF, n=2-962 
12) or dengue (DF, n=4-12) were analysed. (a, b) Plasma levels of IL-18. (c, d) 963 
IL-18Ra expression on MAIT cells. (a, c) Comparison between acute (day 0) and 964 
convalescent (conv) phase (day >10) of infection. (b, d) Comparison between 965 
DHF and DF patients. Correlation of plasma levels of IL-18 (e) or MAIT cell CD38 966 
expression (f) against MAIT cell IL-18Ra expression by Spearman rank 967 
correlation test. (g) Paraffin embedded human liver tissues sections from HCV or 968 
control patients were stained for IL-18 (brown-coloured). Scale bar, 10 mm. (h) 969 
IL-18 mRNA expression in liver biopsies from HCV patients (n=55) relative to 970 
uninfected control liver samples is shown (n=6).  Bars represent means ± s.e.m. 971 
Statistical significance was determined with the Mann-Whitney test (b, d, h) or 972 
Wilcoxon matched-paired test (a, c). ns > 0.05,  *P  0.05, ***P ≤  0.001, ****P ≤  973 
0.0001. Abbreviations: conv, convalescent; DENV, Dengue Virus; DF, dengue 974 
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fever; DHF, dengue haemorrhagic fever; HC, healthy control; HCV, Hepatitis C 975 
Virus. 976 
 977 
Figure 6 MAIT cells respond to Type I Interferons in vitro and in vivo. (a) PBMC’s 978 
from healthy individuals were directly stimulated for 24 h with IFN-α, IFN-β, IL-12, 979 
IL-15, IL-18 or indicated combinations thereof. IFN-γ expression by MAIT cells 980 
(gated on live CD3+CD8+CD161++Vα7.2+ cells) was analysed by flow cytometry. 981 
(b-d) B18R  (IFN-α/β neutralising protein) or PBS control were added to the co-982 
culture (n=6-11). IFN-γ (b), CD69 (c) and Granzyme B (d) expression is shown 983 
relative to the control. Data are representative from at least two independent 984 
experiments. (e) PBMC’s from healthy controls or HCV patients at baseline, 985 
during or end of treatment with either SOF + RBV or SOF + RBV/PEG-IFN were 986 
analysed by flow cytometry. CD69 expression on MAIT cells (gated on live 987 
CD3+CD8+CD161++Vα7.2+ cells) was measured. Bars represent means ± s.e.m. 988 
Statistical significance was determined with the Kruskal-Wallis test followed by 989 
Dunns’ test (a) or Mann-Whitney test (b-e). ns > 0.05,  *P  0.05, ***P ≤  0.001, 990 
****P ≤  0.0001. Abbreviations: HC, healthy controls; PEG-IFN, pegylated 991 
interferon; RBV, Ribavirin; SOF, Sofosbuvir.  992 
 993 
Figure 7 Activated MAIT cells can limit HCV replication. Sorted MAIT cells 994 
(CD8+CD161++Vα7.2+) were rested or activated in a TCR-independent manner 995 
(IL-12 + IL-18 stimulation, MAIT+) for 24 h. (a) IFN-γ expression by MAIT cells 996 
50 
 
(gated on live CD3+CD8+CD161++Vα7.2+ cells) was analysed by flow cytometry. 997 
(b+c) Neat or diluted supernatants were transferred to hepatocyte lines infected 998 
with HCV expressing luciferase and viral replication measured 4 days post 999 
infection (d) Supernatants were transferred to hepatocyte lines infected with HCV 1000 
expressing luciferase repeated in the presence of an isotype control or anti-IFN-γ 1001 
antibody. Data are representative from at least two independent experiments. 1002 
Bars represent means ± s.e.m. Statistical significance was determined with a 1003 
Wilcoxon matched-paired test (c) or Mann-Whitney test (d). **P ≤  0.01. 1004 
Abbreviations: -, unstimulated; HCV, Hepatitis C Virus; luc, luciferase; RLU, 1005 
Relative Light Units; sup, supernatant. 1006 
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Supplementary Figure 1. Specific MAIT cell activation in response to 
viruses.  
(a, b, c) PBMC’s from healthy individuals were co-cultured with autologous 
monocyte derived dendritic cells (DC’s) exposed to Dengue Virus (DENV). 
Proportion of indicated cell population (n=4-8) expressing IFN-γ (a) or TNF-α 
(b) or CD38 (c) in response to DENV or 100 ng/ml PMA and 500 ng/ml 
Ionomycin. (d) MOI-dependent activation of MAIT cells in an influenza virus-
exposed PBMC culture (n=5-8). (e) Percentage of MAIT cells expressing IFN-
γ in response to influenza virus in the following culture conditions: CD8+ T-
cells only (n=20), PBMC only (n=20), or CD8+ T cells co-cultured with 
macrophages either cultured in the presence of GM-CSF (MΦ or GM-MΦ 
(n=15)) or M-CSF (M-MΦ (n=15)), mature Dendritic Cells (mDC (n=15)), 
monocytes (MC (n=15)), THP-1 cells (n=13), immature DC’s (imDC (n=15)) or 
B-cells (n=10). (f) CD8+ T cells isolated from PBMC’s from healthy individuals 
were co-cultured with exposed to HCV in the presence (n=11) in the absence 
of macrophages. IFN-γ expression by indicated cell population. Data are 
representative from at least two independent experiments. Bars represent 
means ± s.e.m.   (g-i) CD8+ T cells isolated from PBMC’s from healthy 
controls co-cultured with macrophages exposed to HCV as described in 
“methods”, unless indicated otherwise. (h, i) Increasing HCV MOI. (h) 
Representative flow cytometry plot. Percentage of CD69 (f, n=4-12) and IFN-γ 
(i, n=4-12) expression by MAIT cells. All data are representative from at least 
two independent experiments. Symbols and bars represent means ± s.e.m. 
Statistical significance Kruskal-Wallis test followed by Dunns’ test (g, j). ns > 
0.05, P  0.05, ****P ≤  0.0001.   
Supplementary Figure 2 
 
Supplementary Figure 2. Triggering of MAIT cells by cytokines.  
(a-c) PBMC’s (n=8) were stimulated for 24 h with the indicated cytokines, or 
combinations thereof. IFN-γ expression in CD161++CD8+ T cells (b) and 
CD161-CD8+ T cells (c) analysed by flow cytometry. (a) Representative plots. 
(d-f) PBMC’s (n=5) were stimulated for 6 days with the indicated cytokine and 
Granzyme B was analysed in MAIT cells (e), CD161-CD8+ T cells and MAIT 
cells (f). Representative dot plots (d). Bars represent means ± s.e.m. 
Statistical significance was determined with Kruskal-Wallis test followed by 
Dunns’ test. ns > 0.05, **P ≤  0.01, ***P ≤  0.001, ****P ≤  0.0001.  
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Supplementary Figure 3 
 
Supplementary Figure 3. Differences in MAIT cell responses in response to 
different cytokines. PBMC’s from healthy individuals (n=3) were stimulated 
with the indicated concentration of a single cytokine (clear symbols) or 
combination of cytokines (black symbols – the concentration of one cytokine 
being fixed as indicated). Symbols represent mean ± s.e.m. (a) TNF-α, (b) 
Granzyme B, and (c) IFN-γ (d) CD69 expression by CD3+CD161++Vα7.2+ 
cells.  
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Supplementary Figure 4 
 
Supplementary Figure 4. Triggering of MAIT cells via toll-like receptors. 
PBMC’s were cultured in the presence of TLR ligands for 24 h in the presence 
or absence of blocking antibodies again IL-12 and IL-18 or MR1. IFN-γ 
expression (top chart) and IL-18Rα (bottom chart) expression by MAIT cells 
were analysed by flow cytometry (gated on live CD3+CD8+CD161++Vα7.2+ 
cells). Representative dot plots of IFN-γ expression are shown in the top 
panel. Data are shown as mean ± SEM and are pooled from two experiments 
performed.  
 
  
Supplementary Figure 5 
 
Supplementary Figure 5. UV-inactivation of viruses and MAIT cell activation.  
UV inactivation of viruses was achieved using a UV lamp (Fisher Scientific 
UVS-18 EL hand held 220V 50Hz 8W 254 nm white light). Cells were 
exposed to (MOI=1): (a) DENV or UV-inactivated DENV (DENV UV) (n=5), (b) 
HCV or UV-inactivated HCV (HCV UV) (n=7), (c) Influenza A virus or UV-
inactivated influenza A virus (n=10). (d) Infection rates of DENV infected 
APC’s (n=9, MOI=1) were confirmed by intracellular staining of the non-
structural DENV protein NS3 by flow cytometry. (e) APC’s (n=4) and Huh7.5 
cells (n=3) were treated with HCV expressing luciferase (MOI=0.1) and 
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luciferase expression was measured 4 days post infection (f). blood-derived 
APC’s (n=3) or embryonic stem cell derived (es) APC’s  (n=3) or MDBK cells 
(n=1) were treated with Influenza A virus (MOI=2). Replication was 
determined using a plaque assay. (g) Correlation of infection rates of DENV 
infected APC’s against MAIT cell IFN-γ expression by Spearman rank 
correlation test. Bars represent means ± s.e.m. Statistical significance was 
determined with Mann-Whitney test. ns > 0.05,  *P  0.05, **P ≤  0.01 
Supplementary Figure 6 
 
Supplementary Figure 6. Viral MAIT cells triggering is mediated by 
cytokines. (a) Influenza Virus-exposed PBMC culture as described in 
“methods”. Isotype control, anti-MR1, anti-IL-12, anti-IL-15 and/or anti-IL-18 
antibodies were added to the co-culture (n=5-29). IFN-γ expression is shown 
relative to the isotype control. Bars represent means ± s.e.m. Statistical 
significance was determined with Kruskal-Wallis test followed by Dunns’ test. 
ns > 0.05, * P  0.05.  (b) IL-15R mRNA expression in HCV-exposed 
macrophages relative to mock at 5 h.   
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Supplementary Figure 7 
 
Supplementary Figure 7. Dose-dependent activation of MAIT cells by IFN-α. 
PBMC’s from healthy individuals (n=3) were stimulated with the indicated 
concentration of IFN-α in combination with IL-18 (50ng/mL). Symbols 
represent mean ± s.e.m. (a) IFN-γ (b) CD69 expression (c) Granzyme B by 
CD3+CD161++Vα7.2+ cells.  
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Supplementary Figure 8. Cytokine-mediated cell activation. 
PBMC’s (n=8) from healthy individuals were directly stimulated for 24 h (black 
bars) with IFN-α, IL-12, IL-15, IL-18 or indicated combinations thereof. Bars 
and symbols represent mean ± s.e.m. IFN-γ expression by 
CD8+CD161++Vα7.2- (a), CD4+CD161++Vα7.2+ (b), CD4-CD8-CD161++Vα7.2- 
(c), or CD8+CD161- T cells (d). Statistical significance was determined with 
Kruskal-Wallis test followed by Dunns’ test. ns > 0.05,  *P  0.05, **P ≤  0.01, 
***P ≤  0.001, ****P ≤  0.0001.  
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Supplementary Figure 9 Bulk CD4 and CD8 T cells do not respond to Type I 
Interferons in vivo. PBMC’s from healthy controls or HCV patients at baseline, 
during or end of treatment with either SOF + RBV or SOF + RBV/PEG-IFN 
were analysed by flow cytometry. CD69 expression on CD4+ T cells (a) or 
CD8+ T cells (b) was measured. Bars represent means ± s.e.m. Statistical 
significance was determined with the Kruskal-Wallis test followed by Mann-
Whitney test. ns > 0.05. Abbreviations: HC, healthy controls; PEG-IFN, 
pegylated interferon; RBV, Ribavirin; SOF, Sofosbuvir.  
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Supplementary Figure 10. Virally activated MAIT cells can limit virus 
replication. Mock or HCV-treated macrophages (MOI=1) were co-cultured with 
CD8+ T-cells from healthy individuals (n=4) for 24 h. Supernatants were 
transferred to hepatocyte lines infected with HCV expressing luciferase 
(MOI=0.1) and viral replication was measured after 96 hours. Data are from 
one experiment with three technical repeats. Bars represent means ± s.e.m. 
Statistical significance was determined with a Wilcoxon matched-paired test. 
***P ≤ 0.001. HCV, Hepatitis C Virus; RLU, Relative Light Units. 
 
 
mo
ck
HC
V
0
1×107
2×107
3×107
H
C
V 
re
pl
ic
at
io
n
(R
LU
)
***
Supplementary Figure 11 
 
 
Supplementary Figure 11. Illustrated model of MAIT cell triggering by 
viruses. In response to viruses, antigen presenting cells, such as Dendritic 
cells, Alveolar Macrophages and Kupffer cells, are able to activate 
CD161++CD8+ T cells, by expressing cytokines, independent of MR1 antigen 
presentation. IL-18 in combination with other innate signals, such as IL-12, IL-
15 and type I IFNs, is critical in stimulating MAIT cells. MAIT-cells highly 
express the IL-18 receptor and in response to stimulation express CD69, 
produce IFN-γ and Granzyme B.   
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Supplementary Figure 12.	   Flow cytometry gating strategy used to define 
MAIT cells.   
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Supplementary Tables 
Supplementary Table 1. Summary of DENV-infected patients enrolled in the 
study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical characteristics of 20 DENV infected patients suffering from dengue 
fever (DF) or dengue haemorrhagic fever (DHF1-4). DHF is divided into four 
grades according to the disease severity: patients with DHF1 and 2 
having increased vascular permeability and patients with DHF3 and 4 
developing shock due to severe plasma loss. Blood samples were obtained 
from these individuals at several time points during the acute and 
convalescent phase of infection. Laboratory confirmation of DENV infection 
and the serotype (DENV1-4) were determined by RT-PCR detection of DENV 
nucleic acid. Abbreviations: DENV, dengue virus; DHF, dengue haemorrhagic 
fever; DF, dengue fever. 
 
 
Patient # Sex JE vac Age Diagnosis Type Serotype 
K01-0029 F Y 13 DHF2 secondary DENV1 
K01-0023 F Y 9 DHF1 secondary DENV1 
K01-0030 M Y 9 DHF1 secondary DENV2 
K02-0032 F N 11 DHF2 secondary DENV2 
K03-0003 M unknown 8 DHF3 secondary DENV1 
K03-0005 M Y 6 DHF2 secondary DENV1 
K02-0018 F N 9 DHF1 secondary DENV2 
K03-0013 M Y 10 DHF1 secondary DENV2 
K03-0092 M N 11 DHF2 secondary DENV1 
K03-0099 M Y 12 DHF1 secondary DENV2 
K03-0038 M Y 5 DHF2 secondary DENV1 
K02-0105 F Y 4 DF secondary DENV2 
K01-0028 M unknown 6 DF secondary DENV1 
K02-0102 F Y 9 DF secondary DENV1 
K02-0105 F Y 4 DF secondary DENV2 
K02-0016 M Y 9 DF secondary DENV1 
K03-0073 F Y 2 DF secondary DENV1 
K02-0037 F Y 12 DF secondary DENV1 
K03-0063 M Y 5 DF secondary DENV2 
K02-0031 M N 12 DF secondary DENV2 
K03-0093 M Y 3 DF secondary DENV4 
K01-0013 M unknown 5 DF primary DENV1 
Supplementary Table 2. Summary of influenza virus-infected patients. 
Patient ID Sex Age Care Co-morbidities 
1 M 48 ICU 
 2 F 59 ICU CLL (since 1992) 
3 F 59 ICU COPD 
4 M 54 ICU COPD 
5 F 29 ICU 5 days post partum 
6 F 45 ward Pregnancy (third trimester) 
7 F 34 ward Pregnancy (third trimester) 
8 M 60 ward Diabetes mellitus,  
    
epilepsy 
9 F 68 ward CLL 
     
Influenza-infected patients were admitted either to the general ward or ICU. 
Patients were recruited from two hospitals based in Oxford and Glasgow 
during the 2009 H1N1 pandemic. Patients had concomitant conditions as 
documented in Table 2, but were not on immunosuppressant at the point of 
sampling. Two patients were pregnant, and one was six days post-partum. 
Abbreviations: CLL, Chronic lymphocytic leukemia; COPD, Chronic 
obstructive pulmonary disease 
 
 
Supplementary Table 3. Summary of HCV-infected patients. 
treatment naïve 
  
relapse 
  patient ID gender age 
 
patient ID gender age 
855 F 44 
 
120 F 64 
672 F 36 
 
144 F 62 
940 M 32 
 
146 M 61 
615 M 41 
 
148 F 63 
765 M 52 
 
152 M 60 
854 M 36 
 
185 F 67 
318 F 49 
 
226 M 47 
581 F 60 
 
279 M 59 
197 F 53 
 
307 F 53 
191 M 64 
 
376 M 59 
256 M 55 
 
205/821 M 53 
603 M 52 
 
sustained virological response 
144 F 47 
 
patient ID gender age 
146 M 56 
 
730 M 59 
148 F 68 
 
134 F 53 
205/821 M 64 
 
292 M 59 
126 M 58 
 
472 M 53 
non-response 
  
325 M 59 
patient ID gender age 
 
618 M 53 
191 M 64 
 
238 M 59 
262 M 62 
 
157 M 53 
306 M 61 
 
400 M 59 
327 M 63 
 
449 M 53 
349 M 60 
 
unkown unkown 
 383 F 67 
 
385 M 53 
391 M 47 
 
spontaneous clearance 
403 F 59 
 
patient ID gender age 
594 M 53 
 
806 M 41 
500 unknown unknown 
 
861 M 55 
602 M 51 
 
884 M 39 
603 M 52 
 
900 M 48 
629 F 51 
 
113 M 67 
634 M 60 
 
975 M 53 
639 F 59 
 
720 F 64 
722 f 63 
 
871 F 62 
    
906 F 61 
    
1014 M 63 
    
1041 M 60 
    
1052 M 67 
   
Samples were collected from the Hepatitis Clinic at the John Radcliffe 
Hospital, Oxford, UK. 
 
 
Supplementary Table 4. Summary of HCV-infected patients (BOSON trial).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PBMC from the BOSON clinical trial were used. BOSON is a randomized, 
open-label, phase 3 study testing Sofosbuvir plus Ribavirin with or without 
pegylated interferon-alpha in patients with HCV Genotype 3 and Treatment-
experienced cirrhotic patients with HCV Genotype 2. PBMCs were processed 
at one of 3 Covance sites (US, Europe, Singapore). 
 
 
 
 
Patient 
Number Treatment 
Collection 
Origin  
HCV 
Genotype  
1 SOF + RBV US 2 
2 SOF + RBV US 3a 
3 SOF + RBV US 3a 
4 SOF + RBV US 2a/2c 
5 SOF + RBV US 3a 
6 SOF + RBV US 3a 
7 SOF + RBV US 3a 
8 SOF + RBV US 3a 
9 SOF + RBV Europe 3a 
10 SOF + RBV Europe 3a 
11 SOF + RBV Europe 3a 
12 SOF + RBV Europe 3c 
13 SOF + RBV Europe 3a 
14 SOF + RBV Europe 3 
15 SOF + RBV Europe 3 
16 SOF + PEG/RBV US 3a 
17 SOF + PEG/RBV US 3a 
18 SOF + PEG/RBV US 3 
19 SOF + PEG/RBV US 3a 
20 SOF + PEG/RBV US 3a 
21 SOF + PEG/RBV US 3a 
22 SOF + PEG/RBV US 3a 
23 SOF + PEG/RBV US 2 
24 SOF + PEG/RBV US 3a 
25 SOF + PEG/RBV US 3b 
